文献速递新发突发、热带与寄生虫病

BioFire全球发热Panel从全血中鉴定疟疾、钩端螺旋体病、基孔肯雅和登革热的临床评估:一项前瞻性、多中心、横断面诊断准确性研究

Clinical evaluation of the BioFire Global Fever Panel for the identification of malaria, leptospirosis, chikungunya, and dengue from whole blood: a prospective, multicentre, cross-sectional diagnostic accuracy study.
PubMed 文献 · Lancet Infect Dis · 2022-06-15

这项前瞻性多中心横断面诊断准确性研究于2018年3月26日至2019年9月30日在全球十个中心连续纳入1965例近期发热的成人和儿童,评估BioFire全球发热Panel检测全血中六种病原体的性能。在1875例可分析结果中,该Panel对基孔肯雅病毒的正符合率为100%(95%CI 86.3-100),对登革病毒为94.0%(90.6-96.5),对钩端螺旋体属为93.8%(69.8-99.8),对疟原虫属为98.3%(96.3-99.4),对恶性疟原虫为92.7%(88.8-95.6),对间日疟或卵形疟原虫为92.7%(86.7-96.6);所有分析物的负符合率均≥99.2%(98.6-99.6)。

要点

  • GF Panel对六种分析物的正符合率为92.7%–100%,负符合率均≥99.2%。
  • 该1小时样本到答案的分子设备可直接在全血中检测急性发热的常见病原体。
  • 检测靶标在全球热带和亚热带地区流行,可能有助于公共卫生监测和个体诊断。

核心结论

  • 这种1小时样本到答案的分子设备可直接在全血中以极好的正符合率和负符合率检测急性发热的常见病原体。
  • 该检测的靶标在全球热带和亚热带地区流行,该检测可能有助于提供公共卫生监测和个体诊断。

研究设计与样本

  • 前瞻性、多中心、横断面诊断准确性研究。
  • 2018年3月26日至2019年9月30日在全球十个中心连续纳入1965例参与者,其中1875例有可分析结果。
  • 纳入过去2天内发热的成人和6个月以上儿童,地点包括撒哈拉以南非洲(加纳、肯尼亚、坦桑尼亚、乌干达)、东南亚(柬埔寨、泰国)、中美洲和南美洲(洪都拉斯、秘鲁)以及美国(华盛顿特区;密苏里州圣路易斯)。
  • 使用不同引物的对照PCR检测随后对同一标本的核酸提取物进行双向测序作为比对方法,计算正符合率和负符合率。
  • 研究注册于ClinicalTrials.gov,NCT02968355。

主要发现

  • 1875例有可分析结果的参与者中,980例(52.3%)为女性,中位年龄22岁(范围0-100)。
  • 1875份标本中657份(35.0%)检出至少一种分析物。
  • GF Panel对基孔肯雅病毒的正符合率为100%(95%CI 86.3-100)。
  • GF Panel对登革病毒的正符合率为94.0%(95%CI 90.6-96.5)。
  • GF Panel对钩端螺旋体属的正符合率为93.8%(95%CI 69.8-99.8),对疟原虫属为98.3%(95%CI 96.3-99.4),对恶性疟原虫为92.7%(95%CI 88.8-95.6),对间日疟或卵形疟原虫为92.7%(95%CI 86.7-96.6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute febrile illness is a common presentation for patients at hospitals globally. Assays that can diagnose a variety of common pathogens in blood could help to establish a diagnosis for targeted disease management. We aimed to evaluate the performance of the BioFire Global Fever Panel (GF Panel), a multiplex nucleic acid amplification test performed on whole blood specimens run on the BioFire FilmArray System, in the diagnosis of several pathogens that cause acute febrile illness. METHODS: We did a prospective, multicentre, cross-sectional diagnostic accuracy study to evaluate the GF Panel. Consenting adults and children older than 6 months presenting with fever in the previous 2 days were enrolled consecutively in sub-Saharan Africa (Ghana, Kenya, Tanzania, Uganda), southeast Asia (Cambodia, Thailand), central and South America (Honduras, Peru), and the USA (Washington, DC; St Louis, MO). We assessed the performance of six analytes (chikungunya virus, dengue virus [serotypes 1-4], Leptospira spp, Plasmodium spp, Plasmodium falciparum, and Plasmodium vivax or Plasmodium ovale) on the GF Panel. The performance of the GF Panel was assessed using comparator PCR assays with different primers followed by bidirectional sequencing on nucleic acid extracts from the same specimen. We calculated the positive percent agreement and negative percent agreement of the GF Panel with respect to the comparator assays. This study is registered with ClinicalTrials.gov, NCT02968355. FINDINGS: From March 26, 2018, to Sept 30, 2019, 1965 participants were enrolled at ten sites worldwide. Of the 1875 participants with analysable results, 980 (52·3%) were female and the median age was 22 years (range 0-100). At least one analyte was detected in 657 (35·0%) of 1875 specimens. The GF Panel had a positive percent agreement for the six analytes evaluated as follows: chikungunya virus 100% (95% CI 86·3-100), dengue virus 94·0% (90·6-96·5), Leptospira spp 93·8% (69·8-99·8), Plasmodium spp 98·3% (96·3-99·4), P falciparum 92·7% (88·8-95·6), and P vivax or P ovale 92·7% (86·7-96·6). The GF Panel had a negative percent agreement equal to or greater than 99·2% (98·6-99·6) for all analytes. INTERPRETATION: This 1 h sample-to-answer, molecular device can detect common causative agents of acute febrile illness with excellent positive percent agreement and negative percent agreement directly in whole blood. The targets of the assay are prevalent in tropical and subtropical regions globally, and the assay could help to provide both public health surveillance and individual diagnoses. FUNDING: BioFire Defense, Joint Project Manager for Medical Countermeasure Systems and US Army Medical Materiel Development Activity, and National Institute of Allergy and Infectious Diseases.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Manabe YC, Betz J, Jackson O, et al. Clinical evaluation of the BioFire Global Fever Panel for the identification of malaria, leptospirosis, chikungunya, and dengue from whole blood: a prospective, multicentre, cross-sectional diagnostic accuracy study. Lancet Infect Dis. 2022. PMID: 35716700. doi:10.1016/S1473-3099(22)00290-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。